Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Moleculin Biotech (MBRX) published a peer-reviewed cardiac safety analysis of Annamycin involving 90 patients across five clinical trials.
The trials included patients with acute myeloid leukemia or metastatic soft tissue sarcoma; 78 had paired heart ultrasounds. Mean left ventricular ejection fraction, a measure of heart pumping function, was 60.6% at baseline and 60.0% after treatment, with no statistically significant change (p=0.84). An independent Cleveland Clinic cardio-oncology evaluation found no clinical or subclinical evidence of treatment-related heart toxicity, including at cumulative exposures above conventional anthracycline lifetime limits. Median cumulative Annamycin dose was 660 mg/m². Annamycin remains under evaluation for relapsed or refractory acute myeloid leukemia.
Positive
- Peer-reviewed analysis published cardiac safety findings from 90 patients across five trials.
- Independent cardiac evaluation found no clinical or subclinical evidence of treatment-related heart toxicity.
- Heart pumping function showed no statistically significant change from 60.6% at baseline to 60.0% after treatment (p=0.84).
- Median cumulative Annamycin dose was 660 mg/m²; findings included exposures above conventional anthracycline lifetime limits.
- Cumulative dose and patient age were not associated with changes in heart pumping function.
Negative
- Paired heart ultrasound data were available for 78 of the 90 treated patients.
- Annamycin remains under clinical evaluation for relapsed or refractory acute myeloid leukemia.
Details
Market move: MBRX -5.42% in the Sep 28 session. pooled cardiac safety analysis
On Sep 28, the day this news came out, MBRX closed 5.42% below the previous close. Argus tracked a trough of -4.2% from its starting point during tracking. Our momentum scanner recorded 2 alerts for this stock that day.
Data tracked by StockTitan Argus for the Sep 28 session.
Key Figures
- Clinical trial count and enrollment
- 5 clinical trials; 90 patients
- Pooled cardiac safety analysis
- Paired echocardiographic data
- 78 patients
- Patients with paired data among the pooled analysis
- Mean LVEF
- 60.6% at baseline; 60.0% following treatment
- No statistically significant difference reported
- LVEF difference p-value
- p=0.84
- Comparison of mean LVEF at baseline and following treatment
- Median cumulative Annamycin dose
- 660 mg/m²
- Pooled clinical analysis
Key Terms
lvef medical
echocardiographic medical
troponin i/t medical
global longitudinal strain medical
anthracyclines medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
– Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline limits
– Independent Cleveland Clinic cardio-oncology evaluation supports continued clinical development of Annamycin as a potentially safer anthracycline
HOUSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced the publication of a peer-reviewed analysis of the cardiac safety of Annamycin (also known as L-Annamycin or naxtarubicin) in Frontiers in Cardiovascular Medicine. The publication, titled “Cardiac safety of L-Annamycin: a pooled analysis of five clinical trials,” reports cardiac safety findings from 90 patients treated across five clinical trials in acute myeloid leukemia (AML) and metastatic soft tissue sarcoma (STS).
The analysis was independently evaluated by a cardio-oncology laboratory at Cleveland Clinic and found no clinical or subclinical evidence of treatment-related cardiotoxicity, including at cumulative Annamycin exposures exceeding traditional lifetime limits for conventional anthracyclines.
“Publication of this comprehensive pooled analysis in a peer-reviewed cardiovascular medicine journal provides additional validation of the cardiac safety profile we have observed with Annamycin across our clinical development program,” said Walter Klemp, Chairman and Chief Executive Officer of Moleculin. “For decades, the clinical utility of anthracyclines has been limited by cumulative cardiotoxicity and associated lifetime dose limits. The absence of detectable cardiac toxicity in patients receiving cumulative doses of Annamycin beyond those traditional thresholds supports our continued development of Annamycin and its potential to address an important limitation of the anthracycline class.”
Pooled Analysis Evaluates Cardiac Safety Across Five Clinical Trials
The publication evaluated cardiac safety data from five sponsor- and investigator-initiated clinical trials, including three trials in AML and two trials in metastatic STS. Across the five studies, 90 patients received Annamycin, with paired echocardiographic data available for 78 patients.
Key findings from the pooled analysis include:
- No significant change in cardiac function: Mean LVEF was
60.6% at baseline compared with60.0% following treatment, with no statistically significant difference (p=0.84). - No relationship between cumulative dose and change in LVEF: The analysis found no association between cumulative Annamycin exposure and changes in LVEF.
- No relationship between age and change in LVEF: Patient age was not associated with changes in LVEF.
- No treatment-related cardiotoxicity identified: Serial ECGs, cardiac biomarkers including troponin I/T, and global longitudinal strain assessments showed no evidence of treatment-related cardiotoxicity.
- High cumulative exposure: Patients received a median cumulative Annamycin dose of 660 mg/m², with findings observed despite cumulative exposures exceeding conventional anthracycline lifetime limits.
The authors concluded that Annamycin was not associated with clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline thresholds and that the findings support continued clinical evaluation of Annamycin as a potentially safer anthracycline platform.
Anthracyclines are among the most widely used and effective classes of cancer medicines, but their use can be limited by cumulative, dose-dependent cardiotoxicity. These cardiac risks can restrict treatment intensity, limit retreatment options and prevent some patients from receiving additional anthracycline therapy.
Annamycin is a fundamentally re-engineered anthracycline designed to maintain the antitumor activity of the anthracycline class while addressing the cardiotoxicity associated with conventional agents. Its liposomal formulation was developed to optimize tissue distribution and reduce cardiac exposure.
The newly published article builds upon previously presented clinical data demonstrating a lack of detectable cardiotoxicity with Annamycin despite cumulative exposure levels substantially exceeding conventional anthracycline limits. Moleculin previously reported that the pooled analysis included 90 patients across five completed clinical trials, with independent cardiac review conducted through the Cleveland Clinic Division of Cardiovascular Medicine.
Annamycin is currently being evaluated in Moleculin’s MIRACLE clinical development program for patients with relapsed or refractory AML.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a Phase 2/3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.
For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential efficacy and safety of Annamycin and AnnAraC in R/R AML, the potential immune-mediated mechanism of action of Annamycin, the relevance of preclinical findings in pancreatic cancer to the treatment of human disease, and the potential for Annamycin to be combined with other agents. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Moleculin's Annamycin cardiac safety analysis find?
An independent cardiac evaluation found no clinical or subclinical evidence of treatment-related heart toxicity across the pooled analysis of five trials. Mean left ventricular ejection fraction was 60.6% at baseline and 60.0% after treatment, without a statistically significant change (p=0.84).
Which cardiac tests were included in Moleculin's Annamycin safety analysis?
The analysis included paired heart ultrasounds, serial electrocardiograms, cardiac biomarkers including troponin I/T, and global longitudinal strain assessments. Paired ultrasound data were available for 78 of the 90 patients treated across the five trials.
Did Annamycin dose or patient age relate to changes in heart function in Moleculin's analysis?
Neither cumulative Annamycin exposure nor patient age was associated with changes in left ventricular ejection fraction, a measure of heart pumping function.